Literature DB >> 21054

The effects of urine pH and plasma protein binding on the renal clearance of disopyramide.

J L Cunningham, D D Shen, I Shudo, D L Azarnoff.   

Abstract

To ascertain whether the renal clearance of disopyramide (pKa = 8.36) is affected by urine pH, the disposition kinetics of disopyramide were compared during excretion of acidic and alkaline urine following both single dose intravenous (2mg/kg) and oral (5 mg/kg) administration to 4 healthy male volunteers. No significant difference was observed in the plasma concentration-time curve of disopyramide. The mean 72 hour recovery of disopyramide and its N-deisopropyl metabolite (MND) in urine was 55.1 and 20.3% of the dose respectively, with no apparent difference between the two routes of administration or pH of urine. Renal clearance of disopyramide was found to vary with time, which is partly the result of a concentration dependent change in plasma protein binding. The unbound fraction of drug in plasma varied from 0.32 to 0.72 between 0.4 to 4microgram/ml concentration. However, time-dependent change in renal clearance of disopyramide persists even after correction for plasma protein binding.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 21054     DOI: 10.2165/00003088-197702050-00004

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  21 in total

1.  The pharmacokinetics of Norpace.

Authors:  A Karim
Journal:  Angiology       Date:  1975-01       Impact factor: 3.619

2.  Determination of disopyramide and its mono-N-dealkylated metabolite in blood serum and urine.

Authors:  T C Hutsell; S J Stachelski
Journal:  J Chromatogr       Date:  1975-03-19

3.  The influence of pH on the buccal absorption and renal excretion of disopyramide in man.

Authors:  S I Ankier; C M Kaye
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

4.  Correlation of disopyramide pharmacokinetics with efficacy in ventricular tachyarrhythmia.

Authors:  R E Rangno; W Warnica; R I Ogilvie; J Kreeft; E Bridger
Journal:  J Int Med Res       Date:  1976       Impact factor: 1.671

5.  Circulatory effects of intravenous disopyramide in heart failure.

Authors:  G Jensen; A Uhrenholt
Journal:  J Int Med Res       Date:  1976       Impact factor: 1.671

6.  Acute termination of cardiac arrhythmias with intravenous disopyramide.

Authors:  H F Mizgala; P R Huvelle
Journal:  J Int Med Res       Date:  1976       Impact factor: 1.671

7.  Haemodynamics of intravenous disopyramide.

Authors:  R Sutton
Journal:  J Int Med Res       Date:  1976       Impact factor: 1.671

8.  The use of disopyramide in the treatment of arrhythmias in ambulatory patients.

Authors:  M B Jones
Journal:  J Int Med Res       Date:  1976       Impact factor: 1.671

9.  Anti-arrhythmic and haemodynamic effects of intravenous and oral disopyramide in patients with ventricular arrhythmia.

Authors:  J Hulting; G Rosenhamer
Journal:  J Int Med Res       Date:  1976       Impact factor: 1.671

10.  Oral disopyramide in prophylaxis of arrhythmias following myocardial infarction.

Authors:  G Jennings; M S Jones; E M Besterman; D G Model; P P Turner; P H Kidner
Journal:  Lancet       Date:  1976-01-10       Impact factor: 79.321

View more
  31 in total

Review 1.  Therapeutic drug monitoring of antiarrhythmic drugs.

Authors:  Gesche Jürgens; Niels A Graudal; Jens P Kampmann
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 2.  Therapeutic drug monitoring: antiarrhythmic drugs.

Authors:  T J Campbell; K M Williams
Journal:  Br J Clin Pharmacol       Date:  1998-10       Impact factor: 4.335

3.  Stereoselective drug disposition: potential for misinterpretation of drug disposition data.

Authors:  A M Evans; R L Nation; L N Sansom; F Bochner; A A Somogyi
Journal:  Br J Clin Pharmacol       Date:  1988-12       Impact factor: 4.335

4.  Quantitative and qualitative binding characteristics of disopyramide in serum from patients with decreased renal and hepatic function.

Authors:  L E Pedersen; J Bonde; N A Graudal; N V Backer; J E Hansen; J P Kampmann
Journal:  Br J Clin Pharmacol       Date:  1987-01       Impact factor: 4.335

5.  Bioavailability of disopyramide in normal volunteers using unbound concentration.

Authors:  J Braun; F Sörgel; W P Gluth; S Oie
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

6.  Role of concentration-dependent plasma protein binding in disopyramide disposition.

Authors:  P J Meffin; E W Robert; R A Winkle; S Harapat; F A Peters; D C Harrison
Journal:  J Pharmacokinet Biopharm       Date:  1979-02

Review 7.  Clinical relevance of pharmacokinetics.

Authors:  G Tognoni; C Bellantuono; M Bonati; M D'Incalci; M Gerna; R Latini; M Mandelli; M G Porro; E Riva
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

8.  Effect of concentration-dependent binding to plasma proteins on the pharmacokinetics and pharmacodynamics of disopyramide.

Authors:  K M Giacomini; T F Blaschke
Journal:  Clin Pharmacokinet       Date:  1984-01       Impact factor: 6.447

9.  Kinetics of disopyramide in decreased hepatic function.

Authors:  J Bonde; N A Graudal; L E Pedersen; S Balsløv; H R Angelo; T L Svendsen; J P Kampmann
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

10.  The effect of saturable binding to plasma proteins on the pharmacokinetic properties of disopyramide.

Authors:  K M Giacomini; S E Swezey; K Turner-Tamiyasu; T F Blaschke
Journal:  J Pharmacokinet Biopharm       Date:  1982-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.